CSIMarket
 


Longeveron Inc   (LGVN)
Other Ticker:  
 
 

LGVN's Gross Income Growth by Quarter and Year

Longeveron Inc 's Gross Income results by quarter and year




LGVN Gross Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -0.13 -0.37 0.00
III Quarter September 0.05 0.09 0.16 0.00
II Quarter June 0.09 0.16 0.21 0.00
I Quarter March 0.08 0.30 0.00 0.00
FY   0.22 0.42 0.00 0.00



LGVN Gross Income third quarter 2023 Y/Y Growth Comment
Longeveron Inc reported fall in Gross Income in the third quarter 2023 by -40% to $ 0.05 millions, from the same quarter in 2022.
Despite modest results in the third quarter 2023, contraction in Longeveron Inc 's Gross Income appears to be smaller than Company's recent average decline.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 158 other companies have achieved higher Gross Income growth. While Longeveron Inc ' s Gross Income drop of -40% ranks overall at the positon no. 3004 in the third quarter 2023.

Explain Gross Income Margin


LGVN Gross Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -40 % -43.75 % - -
II Quarter June -43.75 % -23.81 % - -
I Quarter March -73.33 % - - -
FY   - - - -

Financial Statements
Longeveron Inc 's third quarter 2023 Gross Income $ 0.05 millions LGVN's Income Statement
Longeveron Inc 's third quarter 2022 Gross Income $ 0.09 millions Quarterly LGVN's Income Statement
New: More LGVN's historic Gross Income Growth >>


LGVN Gross Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -40 % -43.75 % -23.81 % -
II Quarter June 12.5 % -46.67 % - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Gross Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #159
Healthcare Sector #442
Overall #3004

Gross Income Y/Y Growth Statistics
High Average Low
-33 % -42.16 % -46.83 %
(Mar 31 2023)   (Jun 30 2023)
Gross Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #159
Healthcare Sector #442
Overall #3004
Gross Income Y/Y Growth Statistics
High Average Low
-33 % -42.16 % -46.83 %
(Mar 31 2023)   (Jun 30 2023)

Gross Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Longeveron Inc 's Q/Q Gross Income Growth


Gross Income Q/Q Growth Statistics
High Average Low
22.37 % -25.98 % -46.67 %
(Jun 30 2023)  


LGVN's III. Quarter Q/Q Gross Income Comment
In the III. Quarter 2023 Longeveron Inc realized fall in Gross Income from the previous quarter by -40% to $ 0.05 millions, from $ 0.09 millions declared in the previous quarter.

When you analyse recent downturn in the III. Quarter 2023, you suppose to take into consideration, that usually III. Quarter 2023 results appear to be sluggish then in the quarter before, Gianna Campbell, market researcher allocated in New York mentioned.

Within Major Pharmaceutical Preparations industry 208 other companies have achieved higher Gross Income quarter on quarter growth. While Longeveron Inc 's Gross Income growth quarter on quarter, overall rank is 3523.


Gross Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #209
Healthcare Sector #556
Overall #3523
Gross Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #209
Healthcare Sector #556
Overall #3523
Gross Income Q/Q Growth Statistics
High Average Low
22.37 % -25.98 % -46.67 %
(Jun 30 2023)  


LGVN's III. Quarter Q/Q Gross Income Comment
In the III. Quarter 2023 Longeveron Inc reported fall in Gross Income sequentially by -40% to $ 0.05 millions, from $ 0.09 millions declared in the previous reporting period.

It's not important problem, as Longeveron Inc 's Gross Income always gravitate to plunge in the III. Quarter.

Within Major Pharmaceutical Preparations industry 208 other companies have achieved higher Gross Income quarter on quarter growth. While Longeveron Inc 's Gross Income growth quarter on quarter, overall rank is 3523.


Longeveron Inc 's 12 Months Gross Income Growth Year on Year


Gross Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Gross Income 12 Months Ending $ 0.10 $ 0.13 $ 0.20 $ 0.43 $ 0.18
Y / Y Gross Income Growth (TTM) -46.67 % -46.83 % -33 % - -
Year on Year Gross Income Growth Overall Ranking # 3131 # 3396 # 0 # 0 # 0
Seqeuential Gross Income Change (TTM) -28.36 % -33.33 % -52.71 % 136.11 % -28.57 %
Seq. Gross Income Growth (TTM) Overall Ranking # 3004 # 3149 # 0 # 3159 # 0




Cumulative Gross Income growth Comment
Longeveron Inc showed decline, but improvement compare to trailing twelve month Gross Income decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Longeveron Inc 's annual Gross Income drop would be -46.67% year on year to $0 millions.

In the Healthcare sector 453 other companies have achieved higher trailing twelve month Gross Income growth. While Total ranking has impoved so far to 3131, from total ranking in previous quarter at 3396.

Gross Income TTM Q/Q Growth Statistics
High Average Low
-33 %
-42.16 %
-46.83 %
 

Gross Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 159
Healthcare Sector # 454
Overall # 3131

Gross Income TTM Y/Y Growth Statistics
High Average Low
-33 %
-42.16 %
-46.83 %
 


Gross Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 159
Sector # 442
S&P 500 # 3004
Cumulative Gross Income growth Comment
Longeveron Inc showed decline, but improvement compare to trailing twelve month Gross Income decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Longeveron Inc 's annual Gross Income drop would be -46.67% year on year to $0 millions.

In the Healthcare sector 453 other companies have achieved higher trailing twelve month Gross Income growth. While Total ranking has impoved so far to 3131, from total ranking in previous quarter at 3396.

Gross Income TTM Q/Q Growth Statistics
High Average Low
-33 %
-42.16 %
-46.83 %
 


Gross Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 159
Healthcare Sector # 454
Overall # 3131

Gross Income TTM Y/Y Growth Statistics
High Average Low
-33 %
-42.16 %
-46.83 %
 


Gross Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 159
Sector # 442
S&P 500 # 3004




Other Gross Income Growth
Major Pharmaceutical Preparations Industry Gross Income Growth Trends and Statistics
Healthcare Sector Gross Income Growth Statistics
Gross Income Growth Trends for overall market
LGVN's Gross Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Income Growth
Lowest Ranking Gross Income Growth
Gross Income Growth for LGVN's Competitors
Gross Income Growth for Longeveron Inc 's Suppliers
Gross Income Growth for LGVN's Customers

You may also want to know
LGVN's Annual Growth Rates LGVN's Profitability Ratios LGVN's Asset Turnover Ratio LGVN's Dividend Growth
LGVN's Roe LGVN's Valuation Ratios LGVN's Financial Strength Ratios LGVN's Dividend Payout Ratio
LGVN's Roa LGVN's Inventory Turnover Ratio LGVN's Growth Rates LGVN's Dividend Comparisons



Companies with similar Gross Income drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Gross Income for the quarter ending Sep 30 2023
Karyopharm Therapeutics Inc -0.19%$ -0.191 millions
Halozyme Therapeutics Inc -0.28%$ -0.277 millions
Envista Holdings Corporation-0.38%$ -0.384 millions
Healthlynked Corp -0.39%$ -0.386 millions
Prestige Consumer Healthcare Inc -0.61%$ -0.614 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Ispecimen inc -1.19%$ -1.187 millions
Icu Medical Inc-1.33%$ -1.328 millions
Phibro Animal Health Corporation-1.34%$ -1.340 millions
Baxter International Inc -1.41%$ -1.412 millions
Lifevantage Corp-1.55%$ -1.549 millions
Optinose Inc -1.98%$ -1.977 millions
Dentsply Sirona Inc -2.56%$ -2.559 millions
Hologic Inc-2.80%$ -2.798 millions
Celularity Inc -2.83%$ -2.829 millions
Gilead Sciences Inc -2.85%$ -2.851 millions
Akumin Inc -3.21%$ -3.205 millions
Viatris Inc -3.27%$ -3.266 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions
Royalty Pharma Plc-3.44%$ -3.437 millions
Standard Biotools Inc -3.47%$ -3.470 millions
Vaso Corporation-3.93%$ -3.933 millions
Puma Biotechnology Inc -3.98%$ -3.979 millions
Orasure Technologies Inc-4.01%$ -4.009 millions
3m Company-4.09%$ -4.086 millions
Abbott Laboratories-4.20%$ -4.203 millions
Charles River Laboratories International inc -4.23%$ -4.229 millions
Mettler toledo International Inc -4.30%$ -4.296 millions
Bristol myers Squibb Company-4.57%$ -4.569 millions
Twist Bioscience Corporation-4.66%$ -4.662 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com